KR101841588B1 - 비경구 크릴 오일의 치료적 적용 - Google Patents

비경구 크릴 오일의 치료적 적용 Download PDF

Info

Publication number
KR101841588B1
KR101841588B1 KR1020147001111A KR20147001111A KR101841588B1 KR 101841588 B1 KR101841588 B1 KR 101841588B1 KR 1020147001111 A KR1020147001111 A KR 1020147001111A KR 20147001111 A KR20147001111 A KR 20147001111A KR 101841588 B1 KR101841588 B1 KR 101841588B1
Authority
KR
South Korea
Prior art keywords
oil
delete delete
composition
emulsion
triglyceride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147001111A
Other languages
English (en)
Korean (ko)
Other versions
KR20140053957A (ko
Inventor
데이비드 에프. 드리스콜
Original Assignee
스테이블 솔루션스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/161,101 external-priority patent/US8895074B2/en
Application filed by 스테이블 솔루션스 엘엘씨 filed Critical 스테이블 솔루션스 엘엘씨
Publication of KR20140053957A publication Critical patent/KR20140053957A/ko
Application granted granted Critical
Publication of KR101841588B1 publication Critical patent/KR101841588B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Insects & Arthropods (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147001111A 2011-06-15 2012-06-13 비경구 크릴 오일의 치료적 적용 Expired - Fee Related KR101841588B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/161,101 2011-06-15
US13/161,101 US8895074B2 (en) 2011-06-15 2011-06-15 Therapeutic application of parenteral krill oil
EP11179821.1 2011-09-02
EP11179821 2011-09-02
PCT/IB2012/001156 WO2012172411A1 (en) 2011-06-15 2012-06-13 Therapeutic application of parenteral krill oil

Publications (2)

Publication Number Publication Date
KR20140053957A KR20140053957A (ko) 2014-05-08
KR101841588B1 true KR101841588B1 (ko) 2018-03-26

Family

ID=46456944

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147001111A Expired - Fee Related KR101841588B1 (ko) 2011-06-15 2012-06-13 비경구 크릴 오일의 치료적 적용

Country Status (22)

Country Link
EP (1) EP2720701B1 (enExample)
JP (1) JP5864735B2 (enExample)
KR (1) KR101841588B1 (enExample)
CN (2) CN103608023A (enExample)
BR (1) BR112013032224B1 (enExample)
CA (1) CA2838312C (enExample)
CY (1) CY1119417T1 (enExample)
DK (1) DK2720701T3 (enExample)
ES (1) ES2643843T3 (enExample)
HR (1) HRP20171431T1 (enExample)
HU (1) HUE036720T2 (enExample)
IL (1) IL229690A (enExample)
LT (1) LT2720701T (enExample)
MX (1) MX351895B (enExample)
PL (1) PL2720701T3 (enExample)
PT (1) PT2720701T (enExample)
RS (1) RS56394B1 (enExample)
RU (1) RU2625760C2 (enExample)
SI (1) SI2720701T1 (enExample)
SM (1) SMT201700470T1 (enExample)
TW (1) TWI592160B (enExample)
WO (1) WO2012172411A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10130600B2 (en) * 2013-05-10 2018-11-20 Memorial Sloan Kettering Cancer Center Lipid scavenging in Ras cancers
GB201402450D0 (en) 2014-02-12 2014-03-26 Aker Biomarine As Liquid phospholipid-containing compositions for preperation of pharmaceuticals
GB201402457D0 (en) 2014-02-12 2014-03-26 Aker Biomarine As Capsules containing high doses of phospholipids
GB201407345D0 (en) 2014-04-25 2014-06-11 Aker Biomarine As Krill Phospholipid compositions
ES2788974T3 (es) * 2014-04-30 2020-10-23 Aker Biomarine Antarctic As Preparaciones de aceite de krill y sus usos
US11147841B2 (en) 2014-12-19 2021-10-19 Aker Biomarine Antarctic As Enhanced omega-3 formulations
AU2016240201A1 (en) * 2015-03-31 2017-05-25 Fresenius Kabi Deutschland Gmbh Emulsions for parenteral administration
CN105901740A (zh) * 2016-04-26 2016-08-31 济南极源生物科技有限公司 一种南极磷虾油可食用营养品
CN117918525A (zh) * 2017-08-10 2024-04-26 儿童医疗中心有限公司 与包含鱼油和/或ω-3脂肪酸的乳剂有关的方法和组合物
EP3536332A1 (en) * 2018-03-07 2019-09-11 Athenion AG Krill oil for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents
KR102451162B1 (ko) * 2020-09-07 2022-10-06 (주)에스디생명공학 효소처리 크릴 오일 추출물을 유효성분으로 포함하는 항염증, 피부 주름개선, 보습 및 피부 재생 촉진용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060078625A1 (en) 2004-10-08 2006-04-13 Susie Rockway Compositions including krill extracts and conjugated linoleic acid and methods of using same
WO2010104575A2 (en) 2009-03-11 2010-09-16 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
WO2011005113A1 (en) * 2009-07-06 2011-01-13 Smartfish As Composition comprising bioactive amino acids and/or peptides and marine oil in a stable oil-in-water emulsion, and the use of said composition as a functional or therapeutic composition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9101642D0 (sv) * 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
JPH08231391A (ja) * 1995-02-24 1996-09-10 Kanagawa Kagaku Kenkyusho:Kk 痴呆症状改善薬
EP1039893B1 (en) * 1997-12-10 2011-02-02 Cyclosporine Therapeutics Limited Pharmaceutical compositions containing an omega-3 fatty acid oil
GB0012597D0 (en) * 2000-05-25 2000-07-12 Astrazeneca Ab Formulation
EP1997498B1 (en) * 2001-06-18 2012-04-25 Neptune Technologies & Bioressources Inc. Krill extracts for prevention and/or treatment of cardiovascular diseases
CN101321477A (zh) * 2005-10-07 2008-12-10 加拿大海洋营养食品有限公司 脂肪酸盐及其制备和使用方法
ZA200904176B (en) * 2006-11-16 2010-08-25 Pronova Biopharma Norge As Process for production of Omega-3 rich marine phospho-lipids from krill
PT2144618E (pt) 2007-03-28 2013-07-08 Aker Biomarine Asa Composições bioeficazes de óleo de krill
EP2153736B1 (en) * 2007-05-11 2017-04-19 Bizen Chemical Co., Ltd. Novel leukotriene receptor antagonist from marine sources
NO327925B1 (no) * 2007-06-25 2009-10-19 Pharmalogica As Anvendelse av kullsyre i drikker omfattende polyumettede fettsyrer (PUFA) for a hindre oksidasjon av fettsyrene.
US20090099261A1 (en) * 2007-09-25 2009-04-16 Isi Brands Inc. Omega-3 mixtures
US20100062057A1 (en) * 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
US20100130619A1 (en) * 2008-11-24 2010-05-27 Joseph Schwarz Pharmaceutical composition for parenteral administration of idebenone
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
NZ599618A (en) * 2009-10-30 2014-08-29 Tharos Ltd Solvent-free process for obtaining phospholipids and neutral enriched krill oils

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060078625A1 (en) 2004-10-08 2006-04-13 Susie Rockway Compositions including krill extracts and conjugated linoleic acid and methods of using same
WO2010104575A2 (en) 2009-03-11 2010-09-16 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
WO2011005113A1 (en) * 2009-07-06 2011-01-13 Smartfish As Composition comprising bioactive amino acids and/or peptides and marine oil in a stable oil-in-water emulsion, and the use of said composition as a functional or therapeutic composition

Also Published As

Publication number Publication date
BR112013032224B1 (pt) 2021-10-13
RS56394B1 (sr) 2017-12-29
LT2720701T (lt) 2017-11-10
PT2720701T (pt) 2017-10-23
JP5864735B2 (ja) 2016-02-17
IL229690A (en) 2017-01-31
DK2720701T3 (en) 2017-10-30
HRP20171431T1 (hr) 2017-12-15
RU2014101067A (ru) 2015-07-20
TW201302209A (zh) 2013-01-16
IL229690A0 (en) 2014-01-30
CY1119417T1 (el) 2018-03-07
WO2012172411A1 (en) 2012-12-20
HUE036720T2 (hu) 2018-07-30
MX2013014901A (es) 2014-07-09
EP2720701A1 (en) 2014-04-23
CN107648268B (zh) 2021-06-22
EP2720701B1 (en) 2017-08-09
SMT201700470T1 (it) 2018-01-11
BR112013032224A2 (pt) 2016-12-20
ES2643843T3 (es) 2017-11-24
JP2014517028A (ja) 2014-07-17
TWI592160B (zh) 2017-07-21
RU2625760C2 (ru) 2017-07-18
PL2720701T3 (pl) 2018-01-31
KR20140053957A (ko) 2014-05-08
CA2838312A1 (en) 2012-12-20
SI2720701T1 (sl) 2017-12-29
MX351895B (es) 2017-11-01
CN107648268A (zh) 2018-02-02
CA2838312C (en) 2019-01-08
CN103608023A (zh) 2014-02-26

Similar Documents

Publication Publication Date Title
KR101841588B1 (ko) 비경구 크릴 오일의 치료적 적용
KR101503970B1 (ko) 오메가-3 풍부화된 비경구 영양 수중-어유 에멀전
KR102118478B1 (ko) 지방산 오일 혼합물 및 계면활성제를 포함하는 조성물, 및 이의 방법 및 용도
US8633253B2 (en) Omega-3 diglyceride emulsions
CN103200965B (zh) 使用ω-3脂肪酸作为肠胃外给药治疗的药物媒介以减少药物不良事件的方法
CA2407764A1 (en) O/w emulsion
CN105939705A (zh) 用于肠胃外给药的包含epa甘油三酯和dha甘油三酯的组合物
US10052352B2 (en) Therapeutic application of parenteral krill oil
US8895074B2 (en) Therapeutic application of parenteral krill oil
CN105939706A (zh) 用于肠胃外给药的包含epa乙酯和dha乙酯的组合物
US20140316001A1 (en) Enriched injectable emulsion containing selected fatty acid triglycerides
HK1244678B (en) Therapeutic application of parenteral krill oil
HK1244678A1 (zh) 磷虾油的胃肠外治疗应用
JP2020503388A (ja) 悪液質を予防及び／又は処置するためのオメガ−３脂肪酸組成物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220320

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220320